Boehringer Ingelheim has entered into a new research and licensing agreement with biotech company Gubra to identify and validate innovative peptides to treat obesity. The new partnership builds
The European Medicines Agency (EMA) has validated the marketing authorization application (MAA) for Pfizer and OPKO’s somatrogon, for review. Somatrogon is a long-acting human growth hormone (hGH) molecule,
Biopharmaceutical firm Merck has announced that it has entered into a definitive agreement to purchase Pandion Therapeutics through a subsidiary, for a total equity value of about $1.85m.
Moderna has announced plans to increase its global manufacturing capacity for Covid-19 vaccine by making additional capital investments. The investments will be made at the company’s owned and
Specialist HIV company ViiV Healthcare has submitted a supplemental new drug application (sNDA) to the US Food and Drug Administration (FDA) to expand the use of Cabenuva. Cabenuva
Belgium-based biopharmaceutical firm UCB has expanded its collaboration with technology company Microsoft to accelerate discovery and development of drugs for people living with severe diseases in immunology and
Pharmaceutical company Pfizer has announced that the US Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for priority review for TicoVac, a tick-borne encephalitis
AstraZeneca has voluntarily withdrawn the Imfinzi (durvalumab) indication for adult patients who received treatment earlier in the US for locally advanced or metastatic bladder cancer. The company has
Biopharmaceutical company Dynavax Technologies (DVAX) has secured marketing authorisation from the European Commission (EC) for Heplisav B, a two-dose adult hepatitis B adjuvanted vaccine. The vaccine is used
Fast Track Designation is a process for facilitating the development and expediting the review of drugs to treat serious medical conditions. The novel and investigational factor VIII therapy
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.